Frontlight ResearchEarly access
TerminatedNo phase
MPS II Immunophenotyping
Key facts
- Who runs it
- Duke University
- Where
- Durham, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 6 people enrolled
- Started
- 1 Apr 2022
- Ended
- 26 Apr 2024
- Type of study
- Observational, 3 groups
- Record updated
- 19 September 2024
- Why it stopped
- Low Enrollment
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Subject has a confirmed diagnosis of Mucopolysaccharidosis type II (MPS II) or Hunter Syndrome based on enzyme activity and variant analysis
- Subject who plan to receive or have received enzyme replacement therapy with idursulfase
Who cannot take part
- None
Where in United States
- Duke UniversityDurham, United States
About the trial
What the trial wants to find out
The purpose of this study is to investigate how participant's body's immune system responds to idursulfase, an enzyme replacement therapy (ERT) and find out which types of immune cells are involved in causing untoward responses to the ERT so that the investigators can relate the level of immune response to the treatment.
The 3 groups in the trial
- Treatment Naive
Subjects who are naïve to ERT and start treatment with idursulfase
- Treatment less than 3 years
Subjects who have received ERT for \<3 years
- Treatment over 3 years
Subjects who have received ERT for 3 or more years
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Immunophenotyping of Patients With MPS II Treated With Enzyme Replacement Therapy
- Record updated
- 19 September 2024